Yixuan Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yixuan Guo has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Bradley R. Cairns
Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Drive, Salt Lake City, UT, 84112, USA
15 shared publications - Kevin B. Jones
Department of Orthopaedics, University of Utah
11 shared publications - Mary L. Nelson
University of Utah 1 Department of Orthopaedics, Spencer Fox Eccles School of Medicine Salt Lake City, Utah
11 shared publications - Xiaoyang Zhang
Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
11 shared publications - Aneasha F. Whittaker-Tademy
Huntsman Cancer Institute 2 Salt Lake City, Utah
10 shared publications - Cedric R. Clapier
Huntsman Cancer Institute 2 Salt Lake City, Utah
10 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Supplemental Figure S3 (associated with Figure 3). WA-68 is variably efficacious against SyS in vivo. A. Necropsy CDX harvest photos from treated MoJo xenografts (mm scaled markings included). B. Harvest photos from treated HS-SY-II CDXs (mm scaled markings included). C. Harvest photos from treated STG048 (magnification bar indicates 2 mm). D. Harvest photos from treated JC2621 (magnification bar indicates 2 mm). E. Representative photomicrographs of hematoxylin and eosin stained (H&E) histology sections from treated MoJo CDXs (magnification bars are 50µm in length). F. The same from HS-SY-II CDXs, showing slightly more spindled cell morphology after WA-68. G. The same from STG017 PDXs, showing increased round cell morphology after WA-68. H. The same from STG048 PDXs, showing increased spindled morphology after WA-68, but no frank necrosis (black magnification bars are 50µm in length; white magnification bar is 2mm in length). I. The same from JC2621 PDXs, showing rounder cell morphology after WA-68, and no frank necrosis (same magnification bars). J. Mid-coronal images from the fluorothymidine PET/MR imaging, showing tumor on the left flank that is FLT avid, T2 hyperintense, and T1 hypointense.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Supplemental Figure S3 (associated with Figure 3). WA-68 is variably efficacious against SyS in vivo. A. Necropsy CDX harvest photos from treated MoJo xenografts (mm scaled markings included). B. Harvest photos from treated HS-SY-II CDXs (mm scaled markings included). C. Harvest photos from treated STG048 (magnification bar indicates 2 mm). D. Harvest photos from treated JC2621 (magnification bar indicates 2 mm). E. Representative photomicrographs of hematoxylin and eosin stained (H&E) histology sections from treated MoJo CDXs (magnification bars are 50µm in length). F. The same from HS-SY-II CDXs, showing slightly more spindled cell morphology after WA-68. G. The same from STG017 PDXs, showing increased round cell morphology after WA-68. H. The same from STG048 PDXs, showing increased spindled morphology after WA-68, but no frank necrosis (black magnification bars are 50µm in length; white magnification bar is 2mm in length). I. The same from JC2621 PDXs, showing rounder cell morphology after WA-68, and no frank necrosis (same magnification bars). J. Mid-coronal images from the fluorothymidine PET/MR imaging, showing tumor on the left flank that is FLT avid, T2 hyperintense, and T1 hypointense.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Supplemental Figure S2 (associated with Figure 2). WA-68 targets BRD9 in cells, molecular structure and administered in vivo. A. Median ± standard deviation for fold-change abundance of each protein calculated from mass spectrometry proteomics of WA-68 versus DMSO control for a sample of 3 at each time point and concentration. B. Cryo-EM derived structural renderings of WA-68 bound between DDB1 (green) supported CRBN (cyan) and BRD9 (pink) C. Close-up of the structural rendering showing glycine 159 of the ZA loop of BRD9 interacting in tight proximity to the linker of WA-68. D. BRD9 and β-actin western blots from splenic tissue and bone marrow in systemic xenografts of MV-4-11 AML into mice after vehicle, or 7 or 24 hours following a single dose of WA-68 at either 4mg/kg intravenous or 20mg/kg subcutaneous injection.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Supplemental Figure S2 (associated with Figure 2). WA-68 targets BRD9 in cells, molecular structure and administered in vivo. A. Median ± standard deviation for fold-change abundance of each protein calculated from mass spectrometry proteomics of WA-68 versus DMSO control for a sample of 3 at each time point and concentration. B. Cryo-EM derived structural renderings of WA-68 bound between DDB1 (green) supported CRBN (cyan) and BRD9 (pink) C. Close-up of the structural rendering showing glycine 159 of the ZA loop of BRD9 interacting in tight proximity to the linker of WA-68. D. BRD9 and β-actin western blots from splenic tissue and bone marrow in systemic xenografts of MV-4-11 AML into mice after vehicle, or 7 or 24 hours following a single dose of WA-68 at either 4mg/kg intravenous or 20mg/kg subcutaneous injection.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Supplemental Figure S4 (associated with Figure 4). BRD9 degradation reduces PBAF and recovers CBAF in SyS. A. Glycerol gradients fractionated nuclear extracts, blotted for a variety of BAF component antibodies after DMSO control or WA-68 exposure for HS-SY-II cells. Green lines indicate the size fractions of GBAF complexes, cyan lines canonical BAF complexes, and purple line PBAF complexes. B. Glycerol gradients fractionated nuclear extracts, blotted for BAF component antibodies after JC2621 PDXs were treated with vehicle control saline or WA-68.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Supplemental Figure S4 (associated with Figure 4). BRD9 degradation reduces PBAF and recovers CBAF in SyS. A. Glycerol gradients fractionated nuclear extracts, blotted for a variety of BAF component antibodies after DMSO control or WA-68 exposure for HS-SY-II cells. Green lines indicate the size fractions of GBAF complexes, cyan lines canonical BAF complexes, and purple line PBAF complexes. B. Glycerol gradients fractionated nuclear extracts, blotted for BAF component antibodies after JC2621 PDXs were treated with vehicle control saline or WA-68.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Supplemental Figure S5 (associated with Figure 5). BRD9 depletion does not compromise GBAF assembly. A. Western blots of the middle-fractions of the glycerol gradient fractionated nuclear extracts from HS-SY-II cells exposed to DMSO or WA-68 in vitro. B. Western blots of the middle-fractions of the glycerol gradient fractionated nuclear extracts from STG048 PDXs exposed to vehicle control saline or WA-68 in vivo. C. Western blots of transfected BioID2 with a V5 tag fused either to the carboxy or amino terminus of BRD9 in the HD-MY-Z cell line, demonstrating doxycycline induction of expression of the fused proteins. D. Mass spectrometry proteomics showing the fold-change (FC) relative abundance of biotinylated proteins in BRD9::BioID2::V5 vs. BioID2::V5::BRD9 transfected HD-MY-Z cells after doxycycline or control (purple dots indicate significance in both experiments.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Supplemental Figure S5 (associated with Figure 5). BRD9 depletion does not compromise GBAF assembly. A. Western blots of the middle-fractions of the glycerol gradient fractionated nuclear extracts from HS-SY-II cells exposed to DMSO or WA-68 in vitro. B. Western blots of the middle-fractions of the glycerol gradient fractionated nuclear extracts from STG048 PDXs exposed to vehicle control saline or WA-68 in vivo. C. Western blots of transfected BioID2 with a V5 tag fused either to the carboxy or amino terminus of BRD9 in the HD-MY-Z cell line, demonstrating doxycycline induction of expression of the fused proteins. D. Mass spectrometry proteomics showing the fold-change (FC) relative abundance of biotinylated proteins in BRD9::BioID2::V5 vs. BioID2::V5::BRD9 transfected HD-MY-Z cells after doxycycline or control (purple dots indicate significance in both experiments.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Supplemental Figure S6 (associated with Figure 6). BRD9 depletion reduces GBAF and fusion oncoprotein enrichment without major changes to chromatin distribution in SyS. A. Heatmap for Pearson correlation coefficients for SS18::SSX, H2AK119ub, GLTSCR1, and other histone post-translational modifications ChIP-seq for individual tumors developed as xenografts of the JC2621 SyS PDX, treated with vehicle. B. Dot plot of the enrichment for merged GLTSCR1 peaks in the JC2621 PDX after treatment with WA-68 versus vehicle. C. Dot plot of enrichment for SS18::SSX in the JC2621 PDX after WA-68 versus vehicle treatment at merged SS18::SSX peaks. D. Venn diagrams of called peaks for each ChIP-seq of SS18::SSX, GLTSCR1, and H2AK119ub in the PDXs STG048 and JC2621. E. Enrichment heatmaps for GLTSCR1 and SS18::SSX of all intersected SS18::SSX+GLTSCR1+H2AK119ub peaks at proximal promoter and distal positions for the PDXs STG048 and JC2621 after WA-68 or vehicle treatments. F. Enrichment heatmaps for GLTSCR1 and SS18::SSX after vehicle or WA-68 treatments at clustered intersection GLTSCR1+SS18::SSX+H2AK119ub proximal sites in JC2621 tumors. G. Enrichment plots for GLTSCR1 and SS18::SSX after vehicle or WA-68 treatments at clustered intersection GLTSCR1+SS18::SSX+H2AK119ub proximal sites in JC2621 tumors.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Supplemental Figure S6 (associated with Figure 6). BRD9 depletion reduces GBAF and fusion oncoprotein enrichment without major changes to chromatin distribution in SyS. A. Heatmap for Pearson correlation coefficients for SS18::SSX, H2AK119ub, GLTSCR1, and other histone post-translational modifications ChIP-seq for individual tumors developed as xenografts of the JC2621 SyS PDX, treated with vehicle. B. Dot plot of the enrichment for merged GLTSCR1 peaks in the JC2621 PDX after treatment with WA-68 versus vehicle. C. Dot plot of enrichment for SS18::SSX in the JC2621 PDX after WA-68 versus vehicle treatment at merged SS18::SSX peaks. D. Venn diagrams of called peaks for each ChIP-seq of SS18::SSX, GLTSCR1, and H2AK119ub in the PDXs STG048 and JC2621. E. Enrichment heatmaps for GLTSCR1 and SS18::SSX of all intersected SS18::SSX+GLTSCR1+H2AK119ub peaks at proximal promoter and distal positions for the PDXs STG048 and JC2621 after WA-68 or vehicle treatments. F. Enrichment heatmaps for GLTSCR1 and SS18::SSX after vehicle or WA-68 treatments at clustered intersection GLTSCR1+SS18::SSX+H2AK119ub proximal sites in JC2621 tumors. G. Enrichment plots for GLTSCR1 and SS18::SSX after vehicle or WA-68 treatments at clustered intersection GLTSCR1+SS18::SSX+H2AK119ub proximal sites in JC2621 tumors.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Supplemental Figure S7 (associated with Figure 7). GBAF remodeler sliding activity increases in the absence of BRD9. A. RNA-seq defined differential expression comparing WA-68 exposure to control DMSO in a control set of maintained active transcription (MAT, expressed genes without fusion and H2AK119ub targeting) following BRD9 degradation in SYO-1 cells. B. Differential expression of sarcomagenesis silenced transcription (SST, not significantly expressed in vehicle treated cells) genes following BRD9 degradation or control in SYO-1 cells. C. Titration sliding assays showing slid and ejected fractions after 60 minutes at variable molar ratios of recombinant nucleosomes to recombinant GBAF with or without BRD9 omitted. Recombinant nucleosomes include H3.3A refers to histone H3.3 variant with C110A mutation introduced to avoid ubiquitin transfer to this residue. Titration assays on recombinant nucleosomes that bear H2A ubiquitination in the octamer show no effect on nucleosome sliding for GBAF wild-type or GBAF lacking BRD9. The absence of BRD9 increases the overall sliding by GBAF. D. Heatmaps and enrichment plots from ATAC-seq and ChIP-seq for GLTSCR1 and SS18::SSX (by HA-tag) at genome-wide distal ATAC-seq sites in the HS-SY-II cell line after exposure to control DMSO or 12, 24, 48, or 96 hours of WA-68 E. The same at loci defined a priori by distal co-localization of called peaks for H2AK119ub, GLTSCR1, and SS18::SSX, termed sarcomagenesis activated transcription (SAT) sites.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Supplemental Figure S7 (associated with Figure 7). GBAF remodeler sliding activity increases in the absence of BRD9. A. RNA-seq defined differential expression comparing WA-68 exposure to control DMSO in a control set of maintained active transcription (MAT, expressed genes without fusion and H2AK119ub targeting) following BRD9 degradation in SYO-1 cells. B. Differential expression of sarcomagenesis silenced transcription (SST, not significantly expressed in vehicle treated cells) genes following BRD9 degradation or control in SYO-1 cells. C. Titration sliding assays showing slid and ejected fractions after 60 minutes at variable molar ratios of recombinant nucleosomes to recombinant GBAF with or without BRD9 omitted. Recombinant nucleosomes include H3.3A refers to histone H3.3 variant with C110A mutation introduced to avoid ubiquitin transfer to this residue. Titration assays on recombinant nucleosomes that bear H2A ubiquitination in the octamer show no effect on nucleosome sliding for GBAF wild-type or GBAF lacking BRD9. The absence of BRD9 increases the overall sliding by GBAF. D. Heatmaps and enrichment plots from ATAC-seq and ChIP-seq for GLTSCR1 and SS18::SSX (by HA-tag) at genome-wide distal ATAC-seq sites in the HS-SY-II cell line after exposure to control DMSO or 12, 24, 48, or 96 hours of WA-68 E. The same at loci defined a priori by distal co-localization of called peaks for H2AK119ub, GLTSCR1, and SS18::SSX, termed sarcomagenesis activated transcription (SAT) sites.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Supplemental Figure S8 (associated with Figure 8). Increased GBAF remodeling in SyS increases H2AK119ub-associated transcription while paradoxically decreasing H2AK119ub enrichment. A. RNA-seq defined differential expression transcriptome wide following exposure of the ASKA, SYO-1, and HS-SY-II SyS cell lines to WA-68 versus DMSO control. B. Gene set enrichment analysis of the differentially expressed genes with the normalized enrichment score (NES) plotted for each tested KEGG Hallmark pathway.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Supplemental Figure S8 (associated with Figure 8). Increased GBAF remodeling in SyS increases H2AK119ub-associated transcription while paradoxically decreasing H2AK119ub enrichment. A. RNA-seq defined differential expression transcriptome wide following exposure of the ASKA, SYO-1, and HS-SY-II SyS cell lines to WA-68 versus DMSO control. B. Gene set enrichment analysis of the differentially expressed genes with the normalized enrichment score (NES) plotted for each tested KEGG Hallmark pathway.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Supplemental Figure S1 (associated with Figure 1). BRD9 depletion arrests proliferation in SyS. A. Western blot indicating depletion efficiency for BRD9 by four doxycycline inducible shRNAs in the human 12733/99 SyS cell line. B. Cell viability after 12 days in culture for shBRD9 versus shControl by doxycycline induction in 12733/99. C. Colony formation assays of 12733/99 cells at 12 days following BRD9 depletion versus control. D. Western blot indicating depletion efficiency for BRD9 by four doxycycline inducible shRNAs in the human HS-SY-II SyS cell line. E. Cell viability after 12 days in culture for shBRD9 versus shControl by doxycycline induction in HS-SY-II. F. Colony formation assays of HS-SY-II cells following BRD9 depletion versus control for 12 days. G. RTqPCR relative expression of SS18::SSX in HS-SY-II cells subjected to four shRNAs directed against the junctional sequence of the fusion oncogene, or two controls. H. Western blot indicating depletion efficiency for SS18::SSX1 by four doxycycline inducible shRNAs and two controls in the human HS-SY-II SyS cell line. I. Cell viability after 12 days in culture for shSS18::SSX versus shControls by doxycycline induction in HS-SY-II. J. Colony formation assays of HS-SY-II cells following SS18::SSX depletion versus control (same as in F). K. Colony formation assays of negative control OVCAR-4 cells following BRD9 depletion versus positive and non-targeted control shRNAs. L. Photomicrographs of Ki-67 immunohistochemistry (ICH) of SYO-1 xenograft samples after treatment with doxycycline or control for non-targeted BRD9 directed shRNAs. M. Western blots showing BRD9 depletion efficiency at indicated time points for in vivo dox-inducible shBRD9 in xenografted HS-SY-II cells. N. Western blots showing BRD9 depletion efficiency at indicated time points for in vivo dox-inducible shBRD9 in xenografted SYO-1 cells.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Supplemental Figure S1 (associated with Figure 1). BRD9 depletion arrests proliferation in SyS. A. Western blot indicating depletion efficiency for BRD9 by four doxycycline inducible shRNAs in the human 12733/99 SyS cell line. B. Cell viability after 12 days in culture for shBRD9 versus shControl by doxycycline induction in 12733/99. C. Colony formation assays of 12733/99 cells at 12 days following BRD9 depletion versus control. D. Western blot indicating depletion efficiency for BRD9 by four doxycycline inducible shRNAs in the human HS-SY-II SyS cell line. E. Cell viability after 12 days in culture for shBRD9 versus shControl by doxycycline induction in HS-SY-II. F. Colony formation assays of HS-SY-II cells following BRD9 depletion versus control for 12 days. G. RTqPCR relative expression of SS18::SSX in HS-SY-II cells subjected to four shRNAs directed against the junctional sequence of the fusion oncogene, or two controls. H. Western blot indicating depletion efficiency for SS18::SSX1 by four doxycycline inducible shRNAs and two controls in the human HS-SY-II SyS cell line. I. Cell viability after 12 days in culture for shSS18::SSX versus shControls by doxycycline induction in HS-SY-II. J. Colony formation assays of HS-SY-II cells following SS18::SSX depletion versus control (same as in F). K. Colony formation assays of negative control OVCAR-4 cells following BRD9 depletion versus positive and non-targeted control shRNAs. L. Photomicrographs of Ki-67 immunohistochemistry (ICH) of SYO-1 xenograft samples after treatment with doxycycline or control for non-targeted BRD9 directed shRNAs. M. Western blots showing BRD9 depletion efficiency at indicated time points for in vivo dox-inducible shBRD9 in xenografted HS-SY-II cells. N. Western blots showing BRD9 depletion efficiency at indicated time points for in vivo dox-inducible shBRD9 in xenografted SYO-1 cells.
- Open Access
- 10 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (18) , OF1-OF19
BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Synovial sarcoma incorporates the SS18::SSX fusion oncoprotein into GLTSCR1-containing BRG1/BRM and associated factors (GBAF) complexes, which confers a dependency on the GBAF subunit BRD9. However, synovial sarcoma clinical trials with multiple BRD9 degraders failed to achieve clinically impactful remissions. In this study, we identified a mechanistic framework to explain these results. BRD9 depletion served to blunt proliferation in synovial sarcoma harboring minimal genomic alterations, rare in trial participants. In cultured cells, xenografts, and recombinant-purified complexes, BRD9 loss did not affect GBAF assembly. Although BRD9 degradation in synovial sarcoma reduced GBAF enrichment at target loci, BRD9-less complexes maintained or increased chromatin accessibility and associated gene transcription. Biochemical assays with purified recombinant GBAF demonstrated increased nucleosome sliding in the absence of BRD9. Together, these findings show that BRD9 restrains GBAF activity, with BRD9 degradation increasing enzymatic remodeling and target gene expression by fusion oncoprotein–distributed GBAFs in synovial sarcoma. This subtle epigenetic disturbance creates a low hurdle for synovial sarcoma to surpass, limiting the therapeutic efficacy of BRD9 degraders. Significance: BRD9 represses the GBAF chromatin remodeling complex, which causes enhanced rather than disrupted SS18::SSX complex activity following BRD9 degradation and explains the lack of efficacy of pharmacological BRD9 degraders in synovial sarcoma.
- 10 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (18) , OF1-OF19
Open AccessBRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma
Synovial sarcoma incorporates the SS18::SSX fusion oncoprotein into GLTSCR1-containing BRG1/BRM and associated factors (GBAF) complexes, which confers a dependency on the GBAF subunit BRD9. However, synovial sarcoma clinical trials with multiple BRD9 degraders failed to achieve clinically impactful remissions. In this study, we identified a mechanistic framework to explain these results. BRD9 depletion served to blunt proliferation in synovial sarcoma harboring minimal genomic alterations, rare in trial participants. In cultured cells, xenografts, and recombinant-purified complexes, BRD9 loss did not affect GBAF assembly. Although BRD9 degradation in synovial sarcoma reduced GBAF enrichment at target loci, BRD9-less complexes maintained or increased chromatin accessibility and associated gene transcription. Biochemical assays with purified recombinant GBAF demonstrated increased nucleosome sliding in the absence of BRD9. Together, these findings show that BRD9 restrains GBAF activity, with BRD9 degradation increasing enzymatic remodeling and target gene expression by fusion oncoprotein–distributed GBAFs in synovial sarcoma. This subtle epigenetic disturbance creates a low hurdle for synovial sarcoma to surpass, limiting the therapeutic efficacy of BRD9 degraders. Significance: BRD9 represses the GBAF chromatin remodeling complex, which causes enhanced rather than disrupted SS18::SSX complex activity following BRD9 degradation and explains the lack of efficacy of pharmacological BRD9 degraders in synovial sarcoma.